Mild to moderate acne Syzygium Effectiveness Safety Acne Herbal product
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Subjects with mild to moderate acne according to FDA's IGA guideline who approved by dermatologist
Exclusion criteria
Exclusion criteria: 1. Pregnant women (confirmed by test kids). 2. Nursing or breast feeding women. 3. Subjects with renal impairment or abnormal of liver enzyme. 4. Subject with other conditions such as wound, skin face abnormal, blood chemistry abnormal that would interfere with the assessments. 5. Subjects with history of allergy to Syzygium extract, sunscreen or other ingredients of experimental product. 6. Subjects with severe acne according to FDA’s IGA. 7. Subjects with acne requiring laser therapy. 8. Subjects with acne requiring isotretinoin or antibiotics such as doxycycline therapy 9. Subjects with acne requiring topical product within 3 months before starting date of study. 10. Subjects with other dermatological conditions such as eczema, seborrheic dermatitis requiring interfering treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Any skin adverse events such as oedema, erythema, hot, scaling, dry skin, itching, pain, skin color At 30 minutes and week 2, 4, 6, 8, 10 , 12 after application the product Report or evaluation of clinical signs and symptoms by physicians and patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of all types of acne, number of non-inflammatory or inflammatory acne, number of comำdone After application product for 2, 4, 6, 8, 10 , and 12 weeks Grading by Physician | — |
Countries
Thailand
Contacts
Department of Medical Science